Shots:
- Antengene has granted UCB a global exclusive license to develop, manufacture, & commercialize ATG-201 for B-cell–related autoimmune diseases, plus access to Antengene’s associated manufacturing tech supporting the therapy
- As per the deal, Antengene will receive $80M in upfront & near-term milestones & ~$1.1B in development & commercial milestones, as well as net sales-based tiered royalties. Further financial details were not disclosed
- Antengene plans to file CTAs for ATG-201 in China & Australia in Q1’26, & conduct P-I studies in both regions, & subsequently transfer further clinical & development activities to UCB
Ref: UCB | Image: Antengene & UCB | Press Release
Related News: UCB Reports the CHMP Positive Opinion of Kygevvi (Doxecitine + Doxribtimine) for Thymidine Kinase 2 Deficiency (TK2d)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
